The United Kingdom and the United States have hammered out a significant commercial pact that will guarantee zero duties on UK medicine products being sold in the US market.
The Terms of the Deal
As part of the deal, the UK has committed to raise funding on pharmaceuticals through the NHS. This pledge guarantees that duties on these crucial products will remain at zero for a period of three years.
This deal is in response to earlier warnings to significantly raise duties on patented pharmaceutical imports, with figures mentioned up to 100%.
"This arrangement with the UK bolsters the worldwide climate for innovative medicines and establishes long-overdue balance to transatlantic medicine commerce," a statement said.
Economic Significance
Drugs represent one of the Britain's largest goods shipped to the US, which is easily the biggest destination for large UK drugmakers.
Statistics show that in the one-year period prior to the third quarter, the UK shipped drugs worth billions to the US. This figure represented nearly one-fifth of total UK exports in that period.
"This deal safeguards employment, increases investment and sets the stage for the UK to emerge as a global hub for medical research," the Business and Trade Secretary commented.
Key UK Commitments
The pact includes several specific commitments from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new therapies to be unaffordable by 25%.
- Increased NHS Spending: There is a aim to increase total health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The amount manufacturers must return to the NHS to prevent overspending will be restricted at 15%. Previously, repayments were more than twenty percent.
Broader Context
This agreement follows a long-running tension between the sector and the British authorities over medicine costs and regulatory access.
These tensions were heightened by assertions that US patients were charged several times more for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several significant manufacturing plans in the UK have been delayed or abandoned, while major expansions have been directed toward projects in the United States.
One official acknowledged that the NHS had to invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the last ten years.
